Bank of New York Mellon
ALLO icon

Bank of New York Mellon’s Allogene Therapeutics ALLO Stock Holding History

Bank of New York Mellon’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Buy
727,182
+331,995
+84% +$729K ﹤0.01% 3115
2026
Q1 		$964K Sell
395,187
-10,656
-3% -$21.4K ﹤0.01% 3232
2025
Q4 		$556K Buy
405,843
+3,972
+1% +$5.24K ﹤0.01% 3549
2025
Q3 		$498K Buy
401,871
+26,834
+7% +$32K ﹤0.01% 3593
2025
Q2 		$424K Buy
375,037
+43,845
+13% +$58.3K ﹤0.01% 3602
2025
Q1 		$484K Buy
331,192
+423
+0.1% +$797 ﹤0.01% 3458
2024
Q4 		$705K Buy
330,769
+13,150
+4% +$32.4K ﹤0.01% 3343
2024
Q3 		$889K Sell
317,619
-44,745
-12% -$119K ﹤0.01% 3203
2024
Q2 		$844K Buy
362,364
+61,811
+21% +$182K ﹤0.01% 3292
2024
Q1 		$1.34M Sell
300,553
-23,428
-7% -$97.8K ﹤0.01% 2992
2023
Q4 		$1.04M Buy
323,981
+13,167
+4% +$37.3K ﹤0.01% 3167
2023
Q3 		$985K Buy
310,814
+1,928
+0.6% +$8.45K ﹤0.01% 3155
2023
Q2 		$1.54M Sell
308,886
-41,283
-12% -$223K ﹤0.01% 2975
2023
Q1 		$1.73M Buy
350,169
+41,747
+14% +$268K ﹤0.01% 2879
2022
Q4 		$1.94M Buy
308,422
+19,900
+7% +$184K ﹤0.01% 2868
2022
Q3 		$3.12M Buy
288,522
+40,141
+16% +$545K ﹤0.01% 2563
2022
Q2 		$2.83M Sell
248,381
-50,866
-17% -$452K ﹤0.01% 2640
2022
Q1 		$2.73M Buy
299,247
+569
+0.2% +$5.93K ﹤0.01% 2767
2021
Q4 		$4.46M Sell
298,678
-20,127
-6% -$355K ﹤0.01% 2524
2021
Q3 		$8.19M Buy
318,805
+36,468
+13% +$866K ﹤0.01% 2232
2021
Q2 		$7.36M Buy
282,337
+60,187
+27% +$1.72M ﹤0.01% 2292
2021
Q1 		$7.84M Sell
222,150
-8,016
-3% -$270K ﹤0.01% 2229
2020
Q4 		$5.81M Buy
230,166
+6,947
+3% +$226K ﹤0.01% 2292
2020
Q3 		$8.42M Sell
223,219
-5,110
-2% -$193K ﹤0.01% 1946
2020
Q2 		$9.78M Buy
228,329
+69,663
+44% +$2.52M ﹤0.01% 1851
2020
Q1 		$3.08M Buy
158,666
+2,076
+1% +$49.4K ﹤0.01% 2314
2019
Q4 		$4.07M Buy
156,590
+8,801
+6% +$242K ﹤0.01% 2436
2019
Q3 		$4.03M Buy
147,789
+13,979
+10% +$398K ﹤0.01% 2388
2019
Q2 		$3.59M Buy
133,810
+55,743
+71% +$1.55M ﹤0.01% 2494
2019
Q1 		$2.26M Buy
78,067
+43,099
+123% +$1.25M ﹤0.01% 2716
2018
Q4 		$941K Buy
+34,968
New +$929K ﹤0.01% 3140

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Bank of New York Mellon's ALLO Position: Q2 2026 in Review

Bank of New York Mellon increased its Allogene Therapeutics (ALLO) stake by 84% in Q2 2026, buying an estimated $729K and bringing the position to 727,182 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3115.

Bank of New York Mellon first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $9.78M in Q2 2020. 95 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Bank of New York Mellon held 727,182 shares of Allogene Therapeutics worth $1.51M as of Q2 2026.
  • Bank of New York Mellon bought 331,995 Allogene Therapeutics shares in Q2 2026, an estimated $729K.
  • Allogene Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3115 holding.
  • Bank of New York Mellon first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Bank of New York Mellon's Allogene Therapeutics position peaked at $9.78M in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.